Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”Pleased to share our new paper out today in the British Journal of Haematology.
This is a post-hoc analysis of the BEYOND trial specifically looking at the proportion of NTDT patients that reached and sustained a hemoglobin level of >10 g/dL while on ß, reflecting clinically meaningful impact considering this would now place them in the ‘safe zone’.”
Read the full article in BJHaem.
Article: Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial
Authors: Khaled Musallam X, Ali T. Taher, John B. Porter, Antonis Kattamis, Mrudula B. Glassberg, Luciana Moro Bueno, Patricia Martin-Regueira, Marta Reverte, Loyse Felber Medlin, Matthew Dyer, Kefeng Wang, Maria Domenica Cappellini
Stay updated on all scientific advances with Hemostasis Today.
-
Dec 13, 2025, 17:38Amaliris Guerra: Science We Do Has Real Human Stakes
-
Dec 13, 2025, 17:31Natasha Jolakoski on Rethinking Lead-in Strategies in VTE
-
Dec 13, 2025, 17:20James Morrissey Shares the Explanation of A Literally 30 Years Worth of TF Biochemistry
-
Dec 13, 2025, 17:03Danny Hsu: Aspirin May Prevent Cancer Metastases?
-
Dec 13, 2025, 16:33Ana Cláudia de Souza: Opening Event for ÁRTEMIS-Brasil, a PROADI-SUS Project
-
Dec 13, 2025, 16:19Chandra Viswanathan on Altruism and Donating Blood
-
Dec 13, 2025, 16:09Brehanna Edwards Compares Apixaban or Rivaroxaban in VTE
-
Dec 13, 2025, 15:36Jeyaraj Pandian’s Visit to China to Support Advancement and Standardization of Stroke Care
-
Dec 13, 2025, 15:20An Important Step Forward in ITP: Shreeram Aradhye Shares Ianalumab Phase III Results!